StockWatch
·

SRF LTD. Q4 FY25 Results

SRFQ4 FY25 Results
Filing
MetricValue (₹ Cr)vs Q3 FY25
Revenue4.3K23.6%
Total Income4.3K23.1%
Expenditure3.6K15.1%
PBT707.3691.8%
Net Profit526.0694.1%
OPM22.20%21.10pp
NPM12.10%4.42pp
EPS17.7594.0%
View full financials

SRF Limited Reports 21% Revenue Growth, 60% PBT Increase in Q4FY25

13 May 2025 · 13 May 2025, 12:40 am

Summary

SRF Limited, a chemical based multi-business entity, announced its consolidated financial results for the fourth quarter and year ended March 31, 2025. The company’s audited results showed a 21% increase in consolidated revenue, 47% increase in EBIT, 60% increase in PBT, and a PAT of ₹526 crore in Q4FY25. The Chemicals Business reported a 30% increase in segment revenue and 50% increase in operating profit. The Performance Films & Foil Business reported a 19% increase in segment revenue and 216% increase in operating profit. The Technical Textiles Business reported a decrease in segment revenue and operating profit. The Other Businesses also reported a decrease in segment revenue and operating profit. In FY25, the company's revenue increased 12% and PBT was nearly unchanged from the previous year.

Key Highlights

  1. 1

    SRF reported a 21% increase in consolidated revenue in Q4FY25

  2. 2

    The company's PBT increased by 60% in Q4FY25

  3. 3

    The Chemicals Business reported a 30% increase in segment revenue and 50% increase in operating profit

  4. 4

    The Performance Films & Foil Business reported a 19% increase in segment revenue and 216% increase in operating profit

  5. 5

    The company's revenue increased 12% in FY25

Management Comments

A

Ashish Bharat Ram

We have finished the year on a very strong note, supported by seasonal factors. That aside, we will go into the new financial year carrying this momentum. However, we are dealing with a very volatile global economy at the moment and while we remain cautiously optimistic about the year ahead, the risks remain

Informational and educational content only. Not investment advice.